Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Chi-Med Starts China Phase II Trial of Surufatinib/Tuoyi Combo in Solid Tumors

publication date: Jan 14, 2020

Hutchison China MediTech (Chi-Med) has started a China Phase II trial of surufatinib in combination with Tuoyi, Shanghai Junshi Bio's approved PD-1 drug, in patients with advanced solid tumors. Surufatinib is an oral anti-angiogenesis VEGFR inhibitor that also inhibits colony stimulating factor-1 receptor (CSF-1R), promoting a macrophage immune response. In June 2019, Chi-Med stopped a Phase III test of surufatinib early because it met its progression-free survival endpoint in patients with neuroendocrine tumors. More details....

Stock Symbols: (AIM/NSDQ: HCM)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China